Inspired by the encouraging therapeutic outcomes of blocking the PD-1/PD-L1 pathway in the treatment of solid tumors, researchers nowadays have tried to integrate PD-1/PD-L1 inhibitors into the treatment course of hematological malignancy (104, 105). Here, PDCD1 is linked to hematologic disorder.